AHK-Cu is a copper peptide marketed almost entirely for hair growth. The laboratory evidence that it acts on hair-follicle cells is real, but the human proof is thin, and it is a cosmetic ingredient — not an approved hair-loss drug. Here is what the science supports, and what it doesn't.
What is AHK-Cu?
AHK-Cu is a small copper-binding peptide: three amino acids — alanine, histidine, and lysine (Ala-His-Lys) — complexed with a copper ion, which is why it is also catalogued as Copper Tripeptide-3. It belongs to the same family as the better-known GHK-Cu: the peptide carries copper into cells and triggers regenerative signalling. AHK-Cu is sold as a cosmetic ingredient and a research compound; it has no approved medical indication, and most of what is known about it comes from cell-culture work. The compound-level data sits on Peptigrity's AHK-Cu profile.
The distinction from GHK-Cu matters and is covered below, but the short version is that the two are close relatives with different amino-acid backbones and very different amounts of supporting research. AHK-Cu is the more follicle-focused of the pair and the far less studied. Almost all of its reputation rests on a single line of in-vitro evidence, which is worth understanding in detail before reading any product claim.
Property | Detail |
|---|---|
Class | Copper-binding tripeptide (Copper Tripeptide-3) |
Sequence | Ala-His-Lys complexed with copper (Cu²⁺) |
Closest relative | GHK-Cu (glycyl-histidyl-lysine copper) |
Primary research focus | Hair-follicle stimulation; skin |
Typical form | Topical cosmetic serum; research powder |
Regulatory status | Cosmetic ingredient / research compound; no approved medical indication |
Evidence base | Mainly in-vitro (cell and follicle culture) |
How does AHK-Cu work?
AHK-Cu's proposed mechanism centres on copper delivery and growth-factor signalling in the hair follicle. The key laboratory finding, from a 2007 study, was that AHK-Cu stimulated the elongation of cultured human hair follicles and promoted the proliferation of dermal papilla cells — which govern the follicle's growth cycle — while reducing their rate of programmed cell death. Researchers have also proposed that it raises vascular endothelial growth factor (VEGF), which supports follicle blood supply, and lowers transforming growth factor beta-1 (TGF-β1), a signal elevated in balding scalp.
One detail from that work has practical consequences and is usually left out of marketing: the effect was biphasic. AHK-Cu stimulated follicle cells at low concentrations but became inhibitory at higher ones, meaning more is not better and concentration matters a great deal in any formulation. It is also important to be precise about what the data is: these are cell-level and cultured-follicle effects, which establish biological plausibility for a hair benefit but do not by themselves demonstrate that applying AHK-Cu grows hair on a person's head.
Proposed mechanism | What it does | Evidence type |
|---|---|---|
Dermal papilla cell proliferation | Increases the follicle's growth-controlling cells | In-vitro (cell culture) |
Anti-apoptotic effect | Keeps follicle cells alive longer | In-vitro (cell culture) |
VEGF stimulation | Supports follicle blood supply (angiogenesis) | Proposed / preclinical |
TGF-β1 reduction | Lowers a signal raised in balding scalp | Proposed / preclinical |
What the evidence actually shows
The honest summary is that AHK-Cu's evidence is real but narrow. The cornerstone is a single 2007 study in Archives of Pharmacal Research, from a Seoul National University group, showing the follicle and dermal-papilla-cell effects described above. It is good in-vitro science and is genuinely the foundation of copper-peptide interest in hair research. But it is in vitro — a controlled laboratory setting, not a clinical trial in people — and human clinical evidence specifically for AHK-Cu is sparse, with most "results" coming from cosmetic-product marketing rather than independent trials.
That gap is the crux. AHK-Cu is not an FDA-approved hair-loss treatment; the only medications approved for androgenetic hair loss are minoxidil and finasteride, both of which have human trial data that AHK-Cu does not. This does not make AHK-Cu useless — the cell-level mechanism is plausible and copper peptides are widely used in cosmetic hair and skin formulations — but it does mean the accurate framing is "a cosmetic ingredient with supportive laboratory evidence," not "a proven hair regrowth therapy." Claims of dramatic hair-count increases should be read with that distinction firmly in mind.
Use / claim | Evidence level | What the data shows |
|---|---|---|
Stimulates follicle cells in culture | In-vitro, solid | 2007 study: follicle elongation, DPC proliferation, anti-apoptosis |
Supports scalp/skin environment | Plausible, indirect | Copper-peptide class effects; cosmetic use |
Regrows hair in humans | Not established | No robust independent clinical trials specific to AHK-Cu |
Approved hair-loss treatment | No | Only minoxidil and finasteride are approved |
AHK-Cu vs GHK-Cu
AHK-Cu and GHK-Cu are frequently treated as interchangeable, and they are not. Both are copper-carrying tripeptides built on a histidine-lysine motif, and both trigger copper-dependent regenerative signalling — but GHK-Cu is far more extensively studied, with a deep literature across wound healing, skin remodelling, and collagen stimulation, while AHK-Cu's research is narrower and more specifically aimed at the hair follicle. In practice, many cosmetic formulations use the two together for complementary effects, and Peptigrity's copper-peptide hair-growth guide covers how they are stacked.
For a buyer, the useful takeaway is to match the compound to the evidence. If the goal is general skin regeneration and anti-aging, GHK-Cu carries the stronger research base; if the interest is specifically follicle stimulation, AHK-Cu is the more targeted molecule but rests on thinner proof. Neither is a substitute for an approved hair-loss medication, and another cosmetic peptide in this category — SNAP-8 — addresses a completely different target (expression lines), so "copper peptide" should not be read as a single interchangeable category.
AHK-Cu | GHK-Cu | |
|---|---|---|
Sequence | Ala-His-Lys + copper | Gly-His-Lys + copper |
Research depth | Narrow (mainly hair, in-vitro) | Extensive (skin, wound healing, collagen) |
Main focus | Hair-follicle stimulation | Skin regeneration, wound healing |
Evidence strength | Thin; cosmetic-grade | Deeper preclinical + cosmetic |
Routes, forms, and use context
AHK-Cu is sold mainly as a topical cosmetic serum for the scalp or skin, and also as a research powder for reconstitution. Topical application has the most plausible cosmetic rationale, since the peptide is designed to act locally on follicle and skin cells. Because the laboratory effect is biphasic — helpful at low concentrations, inhibitory at high ones — formulation concentration genuinely matters, and "stronger" products are not automatically better. Peptigrity does not publish a dosing protocol for AHK-Cu, and nothing here is a recommendation to use it.
For readers comparing application approaches across copper peptides, the GHK-Cu protocol guide lays out topical versus injectable considerations for the better-studied relative; the same general principles about local action and concentration apply. Any decision about using a research compound on the body belongs with a qualified healthcare provider, and cosmetic use should follow the formulator's directions.
Safety, legal status, and verification
Copper peptides used topically at cosmetic concentrations are generally regarded as well tolerated, with skin irritation the most common complaint. Injectable or systemic research use of AHK-Cu, by contrast, has essentially no established human safety data, and copper itself is a metal the body regulates tightly — more is not benign. Legally, AHK-Cu occupies two worlds: a cosmetic ingredient in topical products, and a grey-market "research use only" chemical sold as powder, which is an unregulated channel where identity and purity vary by vendor.
That is why independent verification matters for anyone sourcing research-grade material. On Peptigrity, AHK-Cu currently shows an average HPLC purity of about 99.1% across 14 independent tests from 220 shops (as of June 2026) — a respectable purity figure, but on a small number of tests, and drawn from voluntarily-submitted certificates rather than a random market sample. Two checks carry the weight: HPLC confirms purity, and mass spectrometry confirms the vial actually contains the intended copper tripeptide. Buyers can review the independent lab-test records, compare vendors in the shops directory, learn the workflow in how to test peptides, see the selection-bias context in the purity report, and check rules in the legal-status guide. For the wider category, see the skin and anti-aging pillar.
Frequently Asked Questions
Does AHK-Cu regrow hair?
The laboratory evidence shows AHK-Cu stimulates hair-follicle cells in culture, which makes a hair benefit plausible — but there is no robust independent clinical trial demonstrating that it regrows hair in people. It is best understood as a cosmetic ingredient with supportive in-vitro science, not a proven hair-loss treatment. The only approved medications for pattern hair loss are minoxidil and finasteride.
What's the difference between AHK-Cu and GHK-Cu?
Both are copper-carrying tripeptides, but they have different amino-acid backbones and very different research depth. GHK-Cu is far more studied across skin and wound healing; AHK-Cu is more specifically aimed at the hair follicle but rests on much thinner evidence. They are not interchangeable, though formulations often combine them.
Is AHK-Cu FDA-approved?
No. AHK-Cu is used as a cosmetic ingredient and sold as a research compound, but it holds no approved medical indication for hair loss or anything else. Cosmetic use is regulated differently from drug approval, and no regulator has cleared AHK-Cu as a treatment.
Should AHK-Cu be used topically or injected?
The cosmetic rationale is strongest for topical use, since the peptide is meant to act locally on follicle and skin cells, and topical copper peptides are generally well tolerated. Injectable or systemic use has no established human safety data. This is not a recommendation to use AHK-Cu in any form; that is a decision for a qualified provider.
How is research-grade AHK-Cu verified?
Through independent third-party testing — HPLC for purity and mass spectrometry for identity — from a laboratory the vendor does not own. Identity testing matters because a purity percentage alone does not confirm the vial contains the correct copper tripeptide rather than a related peptide. Peptigrity aggregates these independent results for comparison.
Does Peptigrity recommend an AHK-Cu dose?
No. AHK-Cu is not an approved treatment, and Peptigrity is an independent review platform, not a medical authority. Anyone considering it should consult a licensed provider and, for cosmetic products, follow the formulator's directions.
This article is for educational and informational purposes only and does not constitute medical advice. AHK-Cu is not approved by the FDA or other regulators as a hair-loss treatment or for any medical indication; the evidence for hair benefits is largely in-vitro, and human clinical proof is limited. Research-grade material sold as "research use only" is unregulated, and identity and purity vary. Always consult a qualified healthcare provider before making any decision about a peptide or research compound. Peptigrity is an independent review platform that does not sell, endorse, or recommend specific products or vendors, and earns no advertising, sponsorship, or affiliate revenue.
